Published in Nat Med on August 01, 2000
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 3.06
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol (2008) 3.01
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Squamous cell carcinomas of the head and neck. BMJ (2002) 2.67
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
History of the Baylor Charles A. Sammons Cancer Center. Proc (Bayl Univ Med Cent) (2003) 2.15
Heterochromatin silencing of p53 target genes by a small viral protein. Nature (2010) 2.12
Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest (2001) 2.05
Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta (2008) 1.82
Current issues and future directions of oncolytic adenoviruses. Mol Ther (2009) 1.80
Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68
FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci U S A (2001) 1.67
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther (2004) 1.51
Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev (2010) 1.46
Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44
The relationship between terminal functionalization and molecular weight of a gene delivery polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D organotypic cultures. Biomaterials (2010) 1.37
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J Virol (2006) 1.32
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One (2008) 1.30
Targeting p53 for Novel Anticancer Therapy. Transl Oncol (2010) 1.26
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther (2013) 1.22
Current developments in adenovirus-based cancer gene therapy. Future Oncol (2006) 1.18
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther (2007) 1.14
Adenovirus E1B 55-kilodalton protein: multiple roles in viral infection and cell transformation. J Virol (2009) 1.14
The history of tumor virology. Cancer Res (2008) 1.14
Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J Virol (2010) 1.07
Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol (2010) 1.07
Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev (2010) 1.06
Current gene therapy for stomach carcinoma. World J Gastroenterol (2001) 1.06
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther (2013) 1.04
Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. Br J Cancer (2006) 1.03
Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther (2013) 1.02
E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther (2007) 1.02
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology (2006) 1.02
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets (2012) 1.01
Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models. Biol Direct (2006) 1.01
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther (2007) 0.99
Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Mol Vis (2008) 0.98
Viral vectors for vaccine applications. Clin Exp Vaccine Res (2013) 0.98
Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets (2007) 0.98
Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res (2009) 0.97
In situ adenovirus vaccination engages T effector cells against cancer. Vaccine (2009) 0.97
Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice. Front Oncol (2013) 0.95
Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther (2009) 0.94
Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol (2001) 0.94
Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer (2003) 0.94
Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol (2004) 0.93
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? Viruses (2015) 0.92
Virotherapy against malignant glioma stem cells. Cancer Lett (2009) 0.91
E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. J Virol (2004) 0.91
Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol (2012) 0.90
Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol Sin (2009) 0.90
Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol (2009) 0.90
Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res (2010) 0.90
Is cancer gene therapy an empty suit? Lancet Oncol (2013) 0.90
In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci (2009) 0.89
Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res (2009) 0.89
Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets Ther (2014) 0.89
Cancer stem cells: the final frontier for glioma virotherapy. Stem Cell Rev (2011) 0.89
Lessons learned from next-generation sequencing in head and neck cancer. Head Neck (2012) 0.88
Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia (2001) 0.88
Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J Virol (2001) 0.88
Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound. J Natl Cancer Inst (2013) 0.88
Immunotherapeutic potential of oncolytic vaccinia virus. Front Oncol (2014) 0.88
Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther (2007) 0.88
Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin. J Cancer Res Clin Oncol (2014) 0.87
LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated. Genes Dis (2014) 0.87
Gene therapy: the end of the rainbow? Head Neck Oncol (2009) 0.87
Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics. Biol Direct (2006) 0.87
Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Bone (2006) 0.87
Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors. Mol Cancer (2011) 0.87
p53-based therapeutics for head and neck squamous cell carcinoma. Oral Oncol (2013) 0.86
Bugs as drugs for cancer. Immunology (2002) 0.86
Gene therapy of liver cancer. World J Gastroenterol (2006) 0.86
Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma. World J Gastroenterol (2011) 0.86
Gene therapy for gastric cancer: is it promising? World J Gastroenterol (2006) 0.86
Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci (2009) 0.86
The current state of head and neck cancer gene therapy. Hum Gene Ther (2009) 0.85
Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J Virol (2003) 0.85
Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene. PLoS One (2012) 0.85
Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. Br J Cancer (2003) 0.85
Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells. Prostate (2010) 0.85
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy. Oncolytic Virother (2015) 0.84
Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J Cancer Res Clin Oncol (2004) 0.84
Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer (2011) 0.84
Systemic therapy strategies for head-neck carcinomas: Current status. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.84
cAMP signalling protects proximal tubular epithelial cells from cisplatin-induced apoptosis via activation of Epac. Br J Pharmacol (2012) 0.84
Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system. Mol Cancer (2012) 0.84
Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus. J Theor Biol (2006) 0.84
Loss of FHIT expression in gastric mucosa of patients with family histories of gastric cancer and Helicobacter pylori infection. World J Gastroenterol (2005) 0.83
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol Ther (2010) 0.83
Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation. Cancer Gene Ther (2011) 0.82
Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Ther (2014) 0.82
Therapeutic targeting of tumor suppressor genes. Cancer (2014) 0.82
Directed adenovirus evolution using engineered mutator viral polymerases. Nucleic Acids Res (2010) 0.82
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature (1996) 14.40
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Head and neck cancer. N Engl J Med (1993) 6.33
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer (1968) 4.88
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35
Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet (1997) 4.28
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell (1995) 4.13
Management of malignant teratoma: does referral to a specialist unit matter? Lancet (1993) 3.73
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A (1999) 3.43
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst (1998) 3.17
Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst (1997) 3.03
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature (1997) 2.80
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2000) 2.73
Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res (1989) 2.71
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst (1999) 2.68
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer (2002) 2.53
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med (1996) 2.51
Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res (1970) 2.47
MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther (2008) 2.43
Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst (2000) 2.39
Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2000) 2.34
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res (2000) 2.34
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst (2000) 2.33
BSE transmission to macaques. Nature (1996) 2.32
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med (1996) 2.29
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Unconventional therapies for cancer: a refuge from the rules of evidence? CMAJ (1998) 2.24
Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst (2001) 2.18
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst (1998) 2.16
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst (1994) 2.15
Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst (2001) 2.13
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med (1993) 2.10
Therapy for testicular cancer in Central and Eastern Europe. Lancet (1990) 2.08
Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther (2008) 2.07
Perception of quality of life by patients, partners and treating physicians. Qual Life Res (2000) 2.04
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol (1999) 2.03
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol (2001) 2.03
Quality of cancer care. Ann Oncol (2004) 2.01
Identifying and recruiting healthy control subjects from a managed care organization: a methodology for molecular epidemiological case-control studies of cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.98
Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer (1998) 1.97
A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J (1999) 1.96
Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res (1997) 1.96
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res (2001) 1.93
13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med (1986) 1.90
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol (2007) 1.88
The proliferation of capillary endothelial cells. Cancer Res (1972) 1.81
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.81
Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst (1998) 1.81
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res (2000) 1.81
Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol (1998) 1.79
Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst (1997) 1.79
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst (1992) 1.79
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst (1998) 1.78
Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med (1995) 1.76
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol (1998) 1.76
Medical audit, cancer registration, and survival in ovarian cancer. Lancet (1991) 1.73
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
Brain alpha-bungarotoxin binding protein cDNAs and MAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron (1990) 1.72
Bone metastases: pathophysiology and management policy. J Clin Oncol (1991) 1.70
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer (1980) 1.68
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol (1989) 1.67
Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. Br J Radiol (1972) 1.67
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol (2008) 1.67
Replication-selective adenoviruses as oncolytic agents. J Clin Invest (2000) 1.66
Histopathological and adhesion formation after incision using ultrasonic vibrating scalpel and regular scalpel in the rat. Fertil Steril (1994) 1.66
How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol (1988) 1.65
Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab (2014) 1.65
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood (2001) 1.64
Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol (2002) 1.63
Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood (1991) 1.63
Ovarian stromal tumors containing lutein or Leydig cells (luteinized thecomas and stromal Leydig cell tumors)--a clinicopathological analysis of fifty cases. Int J Gynecol Pathol (1982) 1.63
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol (R Coll Radiol) (2005) 1.61
Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst (1990) 1.61
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59